An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management

被引:17
作者
Chopra, Hitesh [1 ]
Mohanta, Yugal Kishore [2 ]
Rauta, Pradipta Ranjan [3 ]
Ahmed, Ramzan [2 ,4 ]
Mahanta, Saurov [5 ]
Mishra, Piyush Kumar [6 ]
Panda, Paramjot [3 ]
Rabaan, Ali A. [7 ,8 ,9 ]
Alshehri, Ahmad A. [10 ]
Othman, Basim [11 ]
Alshahrani, Mohammed Abdulrahman [10 ]
Alqahtani, Ali S. [12 ]
AL Basha, Baneen Ali [13 ]
Dhama, Kuldeep [14 ]
机构
[1] Chitkara Univ, Chitkara Coll Pharm, Rajpura 140401, Punjab, India
[2] Univ Sci & Technol Meghalaya USTM, Sch Biol Sci, Dept Appl Biol, Nanobiotechnol & Translat Knowledge Lab, 9th Mile, Baridua 793101, Meghalaya, India
[3] AIPH Univ, Sch Biol Sci, Bhubaneswar 754001, Odisha, India
[4] Kasetsart Univ, Fac Sci, Dept Phys, Bangkok 10900, Thailand
[5] Natl Inst Elect & Informat Technol NIELIT, Guwahati Ctr, Gauhati 781008, Assam, India
[6] B N Coll, Dept Bot, Dhubri 783324, Assam, India
[7] Johns Hopkins Aramco Healthcare, Mol Diagnost Lab, Dhahran 31311, Saudi Arabia
[8] Alfaisal Univ, Coll Med, Riyadh 11533, Saudi Arabia
[9] Univ Haripur, Dept Publ Hlth & Nutr, Haripur 22610, Pakistan
[10] Najran Univ, Fac Appl Med Sci, Dept Clin Lab Sci, Najran 61441, Saudi Arabia
[11] Albaha Univ, Fac Appl Med Sci, Dept Publ Hlth, Albaha 65779, Saudi Arabia
[12] King Khalid Univ, Fac Appl Med Sci, Dept Med Lab Sci, Abha 61481, Saudi Arabia
[13] King Fahad Specialist Hosp, Lab Dept, Dammam 32253, Saudi Arabia
[14] ICAR Indian Vet Res Inst, Div Pathol, Bareilly 243122, Uttar Pradesh, India
关键词
tuberculosis; nanotechnology; diagnosis; drug delivery; vaccine; IRON-OXIDE NANOPARTICLES; SURFACE-PLASMON RESONANCE; P-GLYCOPROTEIN SUBSTRATE; MYCOBACTERIUM-TUBERCULOSIS; SILVER NANOPARTICLES; GOLD NANOPARTICLES; EXTRAPULMONARY TUBERCULOSIS; PULMONARY TUBERCULOSIS; RESISTANT TUBERCULOSIS; ANTITUBERCULOSIS DRUGS;
D O I
10.3390/ph16040581
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Tuberculosis (TB), one of the deadliest contagious diseases, is a major concern worldwide. Long-term treatment, a high pill burden, limited compliance, and strict administration schedules are all variables that contribute to the development of MDR and XDR tuberculosis patients. The rise of multidrug-resistant strains and a scarcity of anti-TB medications pose a threat to TB control in the future. As a result, a strong and effective system is required to overcome technological limitations and improve the efficacy of therapeutic medications, which is still a huge problem for pharmacological technology. Nanotechnology offers an interesting opportunity for accurate identification of mycobacterial strains and improved medication treatment possibilities for tuberculosis. Nano medicine in tuberculosis is an emerging research field that provides the possibility of efficient medication delivery using nanoparticles and a decrease in drug dosages and adverse effects to boost patient compliance with therapy and recovery. Due to their fascinating characteristics, this strategy is useful in overcoming the abnormalities associated with traditional therapy and leads to some optimization of the therapeutic impact. It also decreases the dosing frequency and eliminates the problem of low compliance. To develop modern diagnosis techniques, upgraded treatment, and possible prevention of tuberculosis, the nanoparticle-based tests have demonstrated considerable advances. The literature search was conducted using Scopus, PubMed, Google Scholar, and Elsevier databases only. This article examines the possibility of employing nanotechnology for TB diagnosis, nanotechnology-based medicine delivery systems, and prevention for the successful elimination of TB illnesses.
引用
收藏
页数:38
相关论文
共 267 条
[1]   Green synthesis of quaternized chitosan/silver nanocomposites for targeting mycobacterium tuberculosis and lung carcinoma cells (A-549) [J].
Abdel-Aziz, Marwa M. ;
Abu Elella, Mahmoud H. ;
Mohamed, Riham R. .
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2020, 142 :244-253
[2]   Alginate modified-PLGA nanoparticles entrapping amikacin and moxifloxacin as a novel host-directed therapy for multidrug-resistant tuberculosis [J].
Abdelghany, Sharif ;
Parumasivam, Thaigarajan ;
Pang, Angel ;
Roediger, Ben ;
Tang, Patricia ;
Jahn, Kristina ;
Britton, Warwick John ;
Chan, Hak-Kim .
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2019, 52 :642-651
[3]  
Agarwal P., 2013, Adv. Sci. Eng. Med., V5, P709, DOI [10.1166/ASEM.2013.1307, DOI 10.1166/ASEM.2013.1307, 10.1166/asem.2013.1307]
[4]   Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements [J].
Agger, Else Marie ;
Rosenkrands, Ida ;
Hansen, Jon ;
Brahimi, Karima ;
Vandahl, Brian S. ;
Aagaard, Claus ;
Werninghaus, Kerstin ;
Kirschning, Carsten ;
Lang, Roland ;
Christensen, Dennis ;
Theisen, Michael ;
Follmann, Frank ;
Andersen, Peter .
PLOS ONE, 2008, 3 (09)
[5]  
Ahmad Zahoor, 2006, Indian J Chest Dis Allied Sci, V48, P171
[6]   Supramolecular assembly of rifampicin and PEGylated PAMAM dendrimer as a novel conjugate for tuberculosis [J].
Ahmed, Rami ;
Aucamp, Marique ;
Ebrahim, Naushaad ;
Samsodien, Halima .
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2021, 66
[7]   Enhanced protection against pulmonary mycobacterial challenge by chitosan-formulated polyepitope gene vaccine is associated with increased pulmonary secretory IgA and gamma-interferon plus T cell responses [J].
Ai, Wenqing ;
Yue, Yan ;
Xiong, Sidong ;
Xu, Wei .
MICROBIOLOGY AND IMMUNOLOGY, 2013, 57 (03) :224-235
[8]  
Akbari B., 2011, IRANIAN J MAT SCI EN, V8, P48
[9]   Rehabilitation, optimized nutritional care, and boosting host internal milieu to improve long-term treatment outcomes in tuberculosis patients [J].
Akkerman, Onno W. ;
ter Beek, Lies ;
Centis, Rosella ;
Maeurer, Markus ;
Visca, Dina ;
Munoz-Torrico, Marcela ;
Tiberi, Simon ;
Migliori, Giovanni Battista .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 92 :S10-S14
[10]   Nanoparticles as antituberculosis drugs carriers: effect on activity against Mycobacterium tuberculosis in human monocyte-derived macrophages [J].
Anisimova, Y. V. ;
Gelperina, S. I. ;
Peloquin, C. A. ;
Heifets, L. B. .
JOURNAL OF NANOPARTICLE RESEARCH, 2000, 2 (02) :165-171